2-hydroxyethylcarbamate

• 分子结构分类: 有机化合物 - 有机酸及其衍生物 - 羧酸及其衍生物
• 英文名称: 2-hydroxyethylcarbamate
• 英文别名: (2-Hydroxyethyl)carbamate；N-(2-hydroxyethyl)carbamate
• 化学式: C₃H₆NO₃
• 分子量: 104.086
• InChiKey: QENMPTUFXWVPQZ-UHFFFAOYSA-M

计算性质

• 辛醇/水分配系数(LogP)：
  -0.4
• 重原子数：
  7
• 可旋转键数：
  2
• 环数：
  0.0
• sp3杂化的碳原子比例：
  0.67
• 拓扑面积：
  72.4
• 氢给体数：
  2
• 氢受体数：
  3

反应信息

• 作为反应物：
  描述：

  2-hydroxyethylcarbamate 以 水 为溶剂， 生成 二氧化碳 、 C.I.酸性橙108
  参考文献：
  名称：

  Barth, Danielle; Rubini, Patrice; Delpuech, Jean-Jacques, Bulletin de la Societe Chimique de France, 1984, vol. 1, p. 227 - 230

  摘要：

  DOI：
• 作为产物：
  描述：

  二氧化碳 、 C.I.酸性橙108 以 aq. buffer 为溶剂， 生成 2-hydroxyethylcarbamate
  参考文献：
  名称：

  笼中的CO2可直接观察消耗CO2的反应

  摘要：

  如何看到CO 2 太：3-硝基苯基乙酸Photodecarboxylation已被用来释放CO 2的水薄层样品英寸 然后可以通过时间分辨红外光谱法直接，方便地测量CO 2及其反应。

  DOI：

  10.1002/cbic.201200659

文献信息

• Investigation of pyramidal inversion of nitrogen atom in carbamate and thiocarbamate ions formed at the reaction of СО2, СOS, CS2 with 2-aminoethanol
  作者：V. P. Talsi、S. N. Evdokimov

  DOI：10.1134/s1070428017110021

  日期：2017.11

  pyramidal inversion of the nitrogen atom in carbamate and thiocarbamate anions formed at the reaction of 2-aminoethanol with CO2 and COS. The refinement was introduced in formerly suggested cyclic structures of anions containing an intramolecular hydrogen bond NH···O(S), which contradicted the found large values of the barrier of inversion (ΔG ≠ ∼ 70 kJ mol–1). The hydrogen bond in the cyclic anions of

  用动态核磁共振（NMR）测定2-氨基乙醇与CO 2和COS反应生成的氨基甲酸酯和硫代氨基甲酸酯阴离子中氮原子的金字塔倒置的势垒高度的ΔG ≠值。含有分子内氢键NH···O（S）的阴离子的环状结构，与发现的较大的反转位阻值（ΔG ≠〜70 kJ mol –1 ）。氨基甲酸酯和硫代氨基甲酸酯的环状阴离子中的氢键为两个电子和三个中心。在二硫代氨基甲酸酯阴离子（2-氨基乙醇与CS 2反应的产物）的情况下，不会形成具有多中心氢键的类似环状结构。
• Tandem Mass Spectrometry Measurement of the Collision Products of Carbamate Anions Derived from CO₂ Capture Sorbents: Paving the Way for Accurate Quantitation
  作者：Phil Jackson、Keith J. Fisher、Moetaz Ibrahim Attalla

  DOI：10.1007/s13361-011-0161-5

  日期：2011.8.1

  The reaction between CO2 and aqueous amines to produce a charged carbamate product plays a crucial role in post-combustion capture chemistry when primary and secondary amines are used. In this paper, we report the low energy negative-ion CID results for several anionic carbamates derived from primary and secondary amines commonly used as post-combustion capture solvents. The study was performed using the modern equivalent of a triple quadrupole instrument equipped with a T-wave collision cell. Deuterium labeling of 2-aminoethanol (1,1,2,2,-d4-2-aminoethanol) and computations at the M06-2X/6-311++G(d,p) level were used to confirm the identity of the fragmentation products for 2-hydroxyethylcarbamate (derived from 2-aminoethanol), in particular the ions CN−, NCO− and facile neutral losses of CO2 and water; there is precedent for the latter in condensed phase isocyanate chemistry. The fragmentations of 2-hydroxyethylcarbamate were generalized for carbamate anions derived from other capture amines, including ethylenediamine, diethanolamine, and piperazine. We also report unequivocal evidence for the existence of carbamate anions derived from sterically hindered amines (Tris(2-hydroxymethyl)aminomethane and 2-methyl-2-aminopropanol). For the suite of carbamates investigated, diagnostic losses include the decarboxylation product (−CO2, 44 mass units), loss of 46 mass units and the fragments NCO− (m/z 42) and CN− (m/z 26). We also report low energy CID results for the dicarbamate dianion (−O2CNHC2H4NHCO2−) commonly encountered in CO2 capture solution utilizing ethylenediamine. Finally, we demonstrate a promising ion chromatography-MS based procedure for the separation and quantitation of aqueous anionic carbamates, which is based on the reported CID findings. The availability of accurate quantitation methods for ionic CO2 capture products could lead to dynamic operational tuning of CO2 capture-plants and, thus, cost-savings via real-time manipulation of solvent regeneration energies.

  CO2与水合胺反应生成带电的碳酸酯产品，在使用一胺和二胺时在后燃烧捕获化学中发挥着至关重要的作用。本文报告了一些常用于后燃烧捕获溶剂的一胺和二胺衍生的阴离子碳酸酯的低能负离子碰撞解离（CID）结果。该研究采用现代三重四极杆仪器及T波碰撞池进行。对2-氨基乙醇（1,1,2,2,-d4-2-氨基乙醇）的重氮标记以及M06-2X/6-311++G(d,p)水平的计算用于确认2-羟基乙基碳酸酯（源自2-氨基乙醇）裂解产物的身份，特别是离子CN−、NCO−及易于失去的 和水；后者在凝聚态异氰酸酯化学中已有先例。2-羟基乙基碳酸酯的裂解情况为来自其他捕获胺（包括乙二胺、二乙醇胺和哌嗪）的碳酸酯阴离子进行了概括。我们还报告了来源于空间位阻较大的胺（Tris(2-羟基甲基)氨基甲烷和2-甲基-2-氨基丙醇）的碳酸酯阴离子存在的明确证据。对于所研究的一系列碳酸酯，特征性失去包括脱羧产物（− , 44质量单位）、损失46质量单位，以及片段NCO−（m/z 42）和CN−（m/z 26）。我们还报告了在利用乙二胺的 捕获溶液中常遇到的二碳酸酯二阴离子（−O2CNHC2H4NH −）的低能CID结果。最后，我们展示了一种基于离子色谱-MS的有前景的水合阴离子碳酸酯分离和定量程序，该程序基于所报告的CID发现。对于离子 捕获产物的准确定量方法的可用性可能导致 捕获工厂的动态操作调整，从而通过实时操控溶剂再生能量实现成本节约。
• Tetrahydrofuro[3,2-b] pyrrol-3-one intermediates
  申请人：Amura Therapeutics Limited

  公开号：US08039641B2

  公开（公告）日：2011-10-18

  The present invention relates to a process for preparing a compound of formula (Ia), (Ib), (Ic) or (Id), or a pharmaceutically acceptable salt, hydrate, solvate, complex or prodrug thereof, said process comprising the steps of: (A) (i) treating a compound of formula (IVa), where R48 is alkyl or tosyl, with an oxidizing agent to form a compound of formula (Va); and (ii) converting said compound of formula (Va) to a compound of formula (Ia) or (Ic); or (B) (i) treating a compound of formula (IVb), where R48 is alkyl or tosyl, with an oxidizing agent to form a compound of formula (Vb); and (ii) converting said compound of formula (Vb) to a compound of formula (Ib) or (Id).

  本发明涉及一种制备式(Ia)、(Ib)、(Ic)或(Id)化合物的工艺，或其药学上可接受的盐、水合物、溶剂物、复合物或前药，该工艺包括以下步骤：(A) (i)用氧化剂处理式(IVa)化合物，其中R48是烷基或tosyl，以形成式(Va)化合物；(ii)将所述式(Va)化合物转化为式(Ia)或(Ic)化合物；或(B)(i)用氧化剂处理式(IVb)化合物，其中R48是烷基或tosyl，以形成式(Vb)化合物；(ii)将所述式(Vb)化合物转化为式(Ib)或(Id)化合物。
• Furo[3, 2-B] pyrrol-3-ones as cathespin S inhibitors
  申请人：Quibell Martin

  公开号：US08389737B2

  公开（公告）日：2013-03-05

  A first aspect of the invention relates to a compound of formula (I), or a pharmaceutically acceptable salt, hydrate, complex or pro-drug thereof, wherein: one of R3 and R4 is H, and the other is selected from C1-6-alkyl, C1-6-haloalkyl, C1-6-alkoxy, and C6-12-aralkyl; or R3 and R4 are each independently selected from C1-6-alkyl and halo; R9 is a substituted 5 or 6-membered aryl or heteroaryl group or a 6,5- or 6,6-fused biaryl or heterobiaryl group. Compounds of formula (I) exhibit surprisingly high efficacies for human cathepsin S, excellent selectivity verses other mammalian cathepsins and are useful for treatment of diseases such as rheumatoid arthritis, multiple sclerosis, myasthenia gravis, transplant rejection, diabetes, Sjogrens syndrome, Grave's disease, systemic lupus erythematosis, osteoarthritis, psoriasis, idiopathic thrombocytopenic purpura, allergic rhinitis, asthma, atherosclerosis, obesity, chronic obstructive pulmonary disease and chronic pain.

  本发明的第一个方面涉及公式（I）的化合物，或其药物可接受的盐、水合物、复合物或前药，其中：R3和R4中的一个是H，另一个选自C1-6-烷基、C1-6-卤代烷基、C1-6-烷氧基和C6-12-芳基烷基；或者R3和R4各自独立地选自C1-6-烷基和卤代基；R9是取代的5或6元芳基或杂芳基或6,5-或6,6-螺合联的双芳基或双杂芳基。公式（I）的化合物表现出对人类卡特普辛S的惊人高效性，与其他哺乳动物卡特普辛的选择性优异，并可用于治疗风湿性关节炎、多发性硬化症、重症肌无力、移植排斥、糖尿病、Sjogrens综合症、Grave's病、系统性红斑狼疮、骨关节炎、牛皮癣、特发性血小板减少性紫癜、过敏性鼻炎、哮喘、动脉粥样硬化、肥胖症、慢性阻塞性肺疾病和慢性疼痛等疾病的治疗。
• Furo[3,2-B] pyrrol -3-one derivatives and their use as cysteinyl proteinase inhibitors
  申请人：Quibell Martin

  公开号：US08877927B2

  公开（公告）日：2014-11-04

  The present invention relates to compounds of formula (I), and pharmaceutically acceptable salts thereof, A compound of formula (I), or a pharmaceutically acceptable salt, hydrate, complex or pro-drug thereof (I), wherein: one of R1 and R2 is H, and the other is selected from F and Cl, or R1 and R2 are both F; R3 is selected from cyclopentyl and cyclohexyl; R4 is an optionally substituted 5- or 6-membered monocyclic or an 8- to 10-membered bicyclic aryl or heteroaryl ring which includes up to four heteroatoms. The invention further relates to pharmaceutical compositions comprising compounds of formula (I), and the use of such compounds in the treatment of a disease selected from osteoporosis, Paget's disease, Chagas's disease, malaria, gingival diseases, hypercalaemia, metabolic bone disease, diseases involving matrix or cartilage degradation, and bone cancer disorders such as bone metastases and associated pain.

  本发明涉及式(I)的化合物及其药学上可接受的盐、水合物、复合物或前药，其中：R1和R2中的一个是H，另一个选自F和Cl，或者R1和R2都是F；R3选自环戊基和环己基；R4是一个含有最多四个杂原子的5-或6-元单环或8-至10-元双环芳基或杂芳基环，其中可以选用可选取代基。本发明还涉及包含式(I)化合物的制药组合物以及使用这些化合物治疗从骨质疏松症、帕盖特病、查加斯病、疟疾、牙龈疾病、高钙血症、代谢性骨病、涉及基质或软骨降解的疾病以及骨癌疾病如骨转移和相关疼痛等所选择的疾病。